Karyopharm Therapeutics traded at $4.51 this Wednesday June 29th, decreasing $0.07 or 1.53 percent since the previous trading session. Looking back, over the last four weeks, Karyopharm Therapeutics lost 28.18 percent. Over the last 12 months, its price fell by 56.30 percent. Looking ahead, we forecast Karyopharm Therapeutics to be priced at 5.03 by the end of this quarter and at 4.64 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,830.00 31.00 0.82% 2.46%
AbbVie 154.14 1.65 1.08% 36.84%
Abbott 109.10 2.13 1.99% -5.89%
Amgen 245.43 1.92 0.79% 0.69%
Avrobio Inc 1.01 0.05 4.79% -88.64%
AstraZeneca 11,054.00 268.00 2.48% 27.31%
Astrazeneca 67.02 1.09 1.65% 11.89%
BioCryst Pharmaceuticals 10.81 0.35 3.35% -31.63%
Bristol-Myers Squibb 78.28 -0.42 -0.53% 17.15%
Enanta Pharmaceuticals 46.91 2.36 5.30% 6.59%
Epizyme 1.47 -0.01 -0.68% -82.31%
GlaxoSmithKline 1,793.00 27.00 1.53% 26.32%
Incyte Corp 75.89 0.26 0.34% -9.79%
J&J 176.99 0.05 0.03% 7.44%
Karyopharm Therapeutics 4.51 -0.07 -1.53% -56.30%
Eli Lilly 323.00 5.38 1.69% 40.73%
MacroGenics 3.02 0.01 0.33% -88.76%
Merck & Co 92.51 0.62 0.67% 18.95%
Mirati Therapeutics 67.24 -1.26 -1.84% -58.37%
Nektar Therapeutics 3.96 -0.06 -1.49% -76.92%
Novartis 81.19 0.05 0.06% -3.71%
Novartis 84.77 0.60 0.71% -7.09%
Pfizer 50.94 0.28 0.55% 30.08%
Ultragenyx Pharmaceutical 60.24 1.51 2.57% -36.82%
Regeneron Pharmaceuticals 597.62 3.20 0.54% 4.00%
Roche Holding 319.65 2.10 0.66% -8.29%
Sangamo BioSciences 4.14 0.05 1.22% -65.41%
TG Therapeutics 4.32 0.26 6.40% -88.86%
Xencor 27.20 0.14 0.52% -21.14%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%
US2000 1719 -19.47 -1.12% -25.59%

Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.